# Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma

> **NCT00003027** · PHASE3 · COMPLETED · sponsor: **Eastern Cooperative Oncology Group** · enrollment: 482 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** filgrastim
- **BIOLOGICAL:** recombinant interferon alfa
- **DRUG:** cisplatin
- **DRUG:** dacarbazine
- **DRUG:** vinblastine

## Key facts

- **NCT ID:** NCT00003027
- **Lead sponsor:** Eastern Cooperative Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-11-13
- **Primary completion:** 2007-07
- **Final completion:** —
- **Target enrollment:** 482 (ESTIMATED)
- **Last updated:** 2023-06-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003027

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003027, "Combination Chemotherapy With or Without Interleukin-2 and Interferon Alfa in Treating Patients With Metastatic Melanoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00003027. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*